Treats acute lymphoblastic leukemia (ALL). ANDA 210454, held by Eugia Pharma. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 210454 (Methotrexate Sodium), held by Eugia Pharma, was first approved by FDA on Jan 30, 2020, with 3 approved supplements and 0 published complete response letters.
Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen Treatment of adults with mycosis fungoides Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen Treatment of adults with rheumatoid arthritis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) Treatment of adults with severe psoriasis 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 26, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 26, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 30, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters